A Greek chemistry student arrived in America with little English and a dictionary. His journey through Harvard and three pharmaceutical giants now meets its most curious problem: teaching machines to read the chemistry that living things have spent eons writing.
The Montreal drugmaker is spending C$119.33 million to triple injectable capacity and sell its know-how to biotech companies. The bet turns an old factory discipline into a new growth engine - if quality and utilization keep pace.

Across 26 years at Lilly and seven as Neurocrine's chief medical officer, Eiry Roberts learned that drug development is less a straight line than a chain of judgment calls. Her next chapter puts that operating memory to work in the boardroom.